oasis 4 trial semaglutide 🚨 Oral 25 mg delivers double-digit weight loss in OASIS-4 (Phase 3 trial) - Oral Semaglutide 25 mg Demonstrates

Phase 3 TRIUMPH trial dose schedule updates The phase 3 TRIUMPH program expanded on the phase 2 dosing framework, and the recent results add important context to how dose schedules may evolve

From a broader immunologic perspective, Karacabeyli and Lacaille 1 note that GLP-1 RAs may influence shared inflammatory pathways involved in immune-mediated inflammatory diseases (IMIDs), including psoriasis and inflammatory arthritis

Studies consistently show that a portion of rapid weight loss comes from lean muscle mass

Canagliflozin (SGLT2i) contributes to decreased inflammation, extracellular matrix turnover, and fibrosis (300 mg/day decreased plasma levels of TNF receptor 1, IL-6, matrix metalloproteinase 7, and fibronectin 1 after 2 years of follow-up) [93]

Nausea occurred in 16-46% of patients depending on dose, diarrhea in 16-26%, and vomiting in 8-22%

Some of the potential benefits of these GLP-1 medications include: Weight loss Decrease in food noise Reduction in appetite Decrease in stomach emptying so you will feel fuller longer after eating a meal Stimulation of the pancreas to release insulin Lower blood sugar levels Lower blood pressure Improved lipid disorders Improved fatty liver Reduction in the risk of heart and kidney disease Candidates If you suffer from obesity or at least one weight-related condition, you may be a great candidate for semaglutide or tirzepatide